Predicting phenytoin dose - a revised nomogram. 1979

B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens

The nomogram devised by Richens and Dunlop for predicting phenytoin dose has been tested in 127 residential epileptic patients, and the data obtained were used to prepare a revised version of the nomogram. In a further 78 patients, this new version was found to be superior to the original. The mean Km value was found to be 23.8 mumoles/liter. Km was independent of age and body surface area, but Dmax correlated positively with the latter two variables.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
March 1994, International journal of clinical pharmacology and therapeutics,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
December 1975, Lancet (London, England),
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
May 2022, Aging,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
November 1986, Drug intelligence & clinical pharmacy,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
September 1983, Neurology,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
April 1981, Journal of pharmacokinetics and biopharmaceutics,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
February 2015, Burns : journal of the International Society for Burn Injuries,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
June 1987, Therapeutic drug monitoring,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
February 1990, Annals of internal medicine,
B Rambeck, and H E Boenigk, and A Dunlop, and P W Mullen, and J Wadsworth, and A Richens
November 1975, Epilepsia,
Copied contents to your clipboard!